靶向化疗？BRCA1功能失调型乳腺癌中的铂类药物 - Suppr

Suppr

超能文献

Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.

作者信息

Carey Lisa A

出版信息

J Clin Oncol. 2010 Jan 20;28(3):361-3. doi: 10.1200/JCO.2009.24.0838. Epub 2009 Dec 14.

DOI:10.1200/JCO.2009.24.0838

PMID:20008634

Abstract

摘要

相似文献

Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.

J Clin Oncol. 2010 Jan 20;28(3):361-3. doi: 10.1200/JCO.2009.24.0838. Epub 2009 Dec 14.

Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.

Semin Oncol. 2004 Dec;31(6 Suppl 14):25-33. doi: 10.1053/j.seminoncol.2004.11.005.

Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.

Clin Oncol (R Coll Radiol). 2009 Aug;21(6):448-50. doi: 10.1016/j.clon.2009.01.006. Epub 2009 Feb 26.

Choices--and uncertainties--for women with BRCA mutations.

Science. 2003 Oct 24;302(5645):592. doi: 10.1126/science.302.5645.592.

The resurgence of platinum-based cancer chemotherapy.

Nat Rev Cancer. 2007 Aug;7(8):573-84. doi: 10.1038/nrc2167. Epub 2007 Jul 12.

The Renaissance of platinum-based chemotherapy for metastatic breast cancer.

J Chemother. 2008 Oct;20(5):551-60. doi: 10.1179/joc.2008.20.5.551.

High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases.

Cancer Genet Cytogenet. 2010 Feb;197(1):91-4. doi: 10.1016/j.cancergencyto.2009.10.003.

Pharmacogenetics of chemotherapy efficacy in breast cancer.

Pharmacogenomics. 2012 Apr;13(6):677-90. doi: 10.2217/pgs.12.44.

Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.

Semin Oncol. 2004 Dec;31(6 Suppl 14):1-9. doi: 10.1053/j.seminoncol.2004.11.004.

31-year-old female with a prior breast cancer and strong breast cancer family history who continues to menstruate after chemotherapy.

Clin Adv Hematol Oncol. 2003 Mar;1(3):184; discussion 184-5.

引用本文的文献

Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?

Breast Cancer (Dove Med Press). 2021 May 12;13:299-310. doi: 10.2147/BCTT.S306075. eCollection 2021.

Precision medicine for advanced prostate cancer.

Curr Opin Urol. 2016 May;26(3):231-9. doi: 10.1097/MOU.0000000000000278.

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.

The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.

Contemp Oncol (Pozn). 2015;19(1):72-6. doi: 10.5114/wo.2015.50014. Epub 2015 Mar 26.

MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.

Tumour Biol. 2015 Mar;36(3):2065-75. doi: 10.1007/s13277-014-2814-z. Epub 2014 Nov 15.

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.

Breast Cancer Res Treat. 2014 Aug;147(1):185-91. doi: 10.1007/s10549-014-3056-x. Epub 2014 Jul 22.

BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer.

Mol Cancer Res. 2011 Aug;9(8):1078-90. doi: 10.1158/1541-7786.MCR-11-0155. Epub 2011 Jun 23.

Are current development programs realising the full potential of new agents?

Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S23. doi: 10.1186/bcr2752.

Triple-negative breast cancer: disease entity or title of convenience?

Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28.

Molecular basis for therapy resistance.

Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.

J Clin Oncol. 2010 Jan 20;28(3):361-3. doi: 10.1200/JCO.2009.24.0838. Epub 2009 Dec 14.

Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.

Semin Oncol. 2004 Dec;31(6 Suppl 14):25-33. doi: 10.1053/j.seminoncol.2004.11.005.

Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.

Clin Oncol (R Coll Radiol). 2009 Aug;21(6):448-50. doi: 10.1016/j.clon.2009.01.006. Epub 2009 Feb 26.

Choices--and uncertainties--for women with BRCA mutations.

Science. 2003 Oct 24;302(5645):592. doi: 10.1126/science.302.5645.592.

The resurgence of platinum-based cancer chemotherapy.

Nat Rev Cancer. 2007 Aug;7(8):573-84. doi: 10.1038/nrc2167. Epub 2007 Jul 12.

The Renaissance of platinum-based chemotherapy for metastatic breast cancer.

J Chemother. 2008 Oct;20(5):551-60. doi: 10.1179/joc.2008.20.5.551.

High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases.

Cancer Genet Cytogenet. 2010 Feb;197(1):91-4. doi: 10.1016/j.cancergencyto.2009.10.003.

Pharmacogenetics of chemotherapy efficacy in breast cancer.

Pharmacogenomics. 2012 Apr;13(6):677-90. doi: 10.2217/pgs.12.44.

Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.

Semin Oncol. 2004 Dec;31(6 Suppl 14):1-9. doi: 10.1053/j.seminoncol.2004.11.004.

31-year-old female with a prior breast cancer and strong breast cancer family history who continues to menstruate after chemotherapy.

Clin Adv Hematol Oncol. 2003 Mar;1(3):184; discussion 184-5.

引用本文的文献

Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?

Breast Cancer (Dove Med Press). 2021 May 12;13:299-310. doi: 10.2147/BCTT.S306075. eCollection 2021.

Precision medicine for advanced prostate cancer.

Curr Opin Urol. 2016 May;26(3):231-9. doi: 10.1097/MOU.0000000000000278.

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.

The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.

Contemp Oncol (Pozn). 2015;19(1):72-6. doi: 10.5114/wo.2015.50014. Epub 2015 Mar 26.

MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.

Tumour Biol. 2015 Mar;36(3):2065-75. doi: 10.1007/s13277-014-2814-z. Epub 2014 Nov 15.

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.

Breast Cancer Res Treat. 2014 Aug;147(1):185-91. doi: 10.1007/s10549-014-3056-x. Epub 2014 Jul 22.

BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer.

Mol Cancer Res. 2011 Aug;9(8):1078-90. doi: 10.1158/1541-7786.MCR-11-0155. Epub 2011 Jun 23.

Are current development programs realising the full potential of new agents?

Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S23. doi: 10.1186/bcr2752.

Triple-negative breast cancer: disease entity or title of convenience?

Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28.

Molecular basis for therapy resistance.

Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24.